On October 16, SBP GROUP rose 3.23% in Regular Trading, trading at HK$5.445, with turnover of HK$35.63 million.
The move was accompanied by fresh attention on the company’s hepatitis B pipeline and continued capital return activity. Its subsidiary Chia Tai Tianqing said clinical results for TQ-A3334, a TLR7 agonist, were selected as a late-breaking abstract at the AASLD annual meeting and will be presented orally. Bepirovirsen, a partnered product with GSK, was also selected for two oral presentations and eight poster presentations, increasing market focus on the company’s hepatitis B innovation portfolio.
Separately, the company disclosed on October 14 that it repurchased 8.0 million shares for HK$41.32 million, with the repurchased shares intended for cancellation. The Pharmaceuticals sector was also firmer, with CSPC PHARMA, HANSOH PHARMA and SIMCERE PHARMA among the gainers, reinforcing the stock’s rise.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
